J BUON [JOURNAL]
Sun
200 papers
Stereotactic radiosurgery for the treatment of esophageal carcinoma brain metastases.
Zheng C, Weng Y, Xu Q
J BUON · 2021 · PMID 34761626
PURPOSE: The authors evaluated the results of stereotactic radiosurgery (SRS) for the treatment of metastatic brain tumors from esophageal carcinoma. METHODS: We retrospectively analyzed the clinical characteristics and...
PURPOSE: The authors evaluated the results of stereotactic radiosurgery (SRS) for the treatment of metastatic brain tumors from esophageal carcinoma. METHODS: We retrospectively analyzed the clinical characteristics and treatment outcomes in 21 patients with metastatic brain tumors from esophageal carcinoma who underwent SRS between July 2011 and February 2019. RESULTS: 21 patients (25 SRS procedures) of a total of 88 tumors underwent Gamma knife SRS. Tumor histology was adenocarcinoma in 6 patients (28.6%) and squamous cell carcinoma in 15 patients (71.4%). The median age was 66 years (range 58-73). Eleven patients (52.4%) presented with multiple metastases (range 2-11), and 10 . (47.6%) with a single metastasis. The median tumor volume was 0.55 cm3 (range 0.004-44.64 cm3). No complications related to radiosurgical treatment were identified. The local tumor control rate in this group was 94.2 %. The median survival time from the diagnosis of esophageal cancer was 22 months and the median survival from SRS was 16 months. Higher Karnofsky Performance Scale (KPS) at the time of procedure was associated with increased survival (p=0.003). After SRS, 4 patients had subsequent SRS (1 for boost therapy, 3 for new metastatic deposits), 1 patient underwent craniotomy due to tumor progression. Of the 19 patients who have died, 17 (89.5%) succumbed to systemic disease progression and 2 (10.5%) had neurologic deaths. CONCLUSION: SRS is an effective and minimally invasive treatment that can prolong survival. Accordingly, SRS could be used as the initial treatment modality, if possible, even in patients with multiple metastases.
Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
Tural D, Akar E, Baytekin HF … +3 more , Canoglu D, Yilmaz M, Tugcu V
J BUON · 2021 · PMID 34761625
PURPOSE: Platin-based chemotherapies are first-line treatment methods after surgery in bladder cancer. Recently, novel immunotherapies emerged after platin-based regimens. The purpose of this study was to evaluate the pr...
PURPOSE: Platin-based chemotherapies are first-line treatment methods after surgery in bladder cancer. Recently, novel immunotherapies emerged after platin-based regimens. The purpose of this study was to evaluate the prognostic significance of microsatellite instability (MSI), tumor infiltrating lymphocytes (TILs) and programmed cell death ligand-1 (PD-L1) expression which are used as predictive biomarkers in immunotherapy. METHODS: Clinical and pathological features of bladder cancer patients who underwent radical cystectomy were retrospectively analyzed from their records in this single-center study. PD-L1, PD-L1 on TIL, PMS2, MSH2, MSH6 and MLH1 immunohistochemistry staining were carried out to archieve resected tumor specimens of the eligible patients. MSI was evaluated according to existing of PMS2, MSH2, MSH6 and MLH1. RESULTS: MSI was high in 24.6% of 61 patients. PD-L1 expression on tumor cells and PD-L1 expression on TIL were positive in 14.8% and 16.4% of the patients, respectively. Intratumoral TIL rate was >10% in 12 patients (19.7%). There was no statistically significant relationship between PD-L1, PD-L1 on TIL, MSI and TIL rate and patients' characteristics including sex, stage, pathologic grade and lymph node status. There was a positive trend between MSI-high patients and overall survival (OS) (p=0.089). Univariate analysis did not reveal any significant difference at 3-years OS with PD-L1 tumor expression and PD-L1 expression on TIL and TIL rate >10% (p=0.822, p=0.638, p=0.318, respectively) Conclusion: This study revealed that there is a positive trend between OS and MSI but no prognostic significance of PD-L1 and TIL which are proven predictive biomarkers of immunotherapy in patients with bladder cancer.
BTBD7 accelerates the epithelial-mesenchymal transition, proliferation and invasion of prostate cancer cells.
Chen B, Liu C, Bai G … +2 more , Zhu Y, Xu H
J BUON · 2021 · PMID 34761624
PURPOSE: To investigate the potential function of BTBD7 in prostate cancer (PCa) development and the underlying molecular mechanism. METHODS: Serum levels of BTBD7 in PCa patients were examined by qRT-PCR. Regulatory eff...
PURPOSE: To investigate the potential function of BTBD7 in prostate cancer (PCa) development and the underlying molecular mechanism. METHODS: Serum levels of BTBD7 in PCa patients were examined by qRT-PCR. Regulatory effects of BTBD7 on viability and invasiveness were detected by CCK-8 and Transwell assay, respectively. Moreover, Western blot analysis was conducted to examine protein levels of epithelial-mesenchymal transition (EMT) markers (E-cadherin and N-cadherin) in PCa cells intervened by BTBD7. RESULTS: Serum level of BTBD7 was increased in PCa patients, especially those with Gleason score ≥8 or TNM staging Ⅲ+Ⅳ. Knockdown of BTBD7 attenuated the viability and invasiveness of PCa cells, which upregulated E-cadherin and downregulated N-cadherin. CONCLUSION: Serum level of BTBD7 increases in PCa patients. It accelerates PCa development by triggering proliferative and invasive potentials, as well as EMT.
The evaluation of sexual functions of prostate cancer patients receiving radiotherapy.
Guzle Adas Y, Kekilli E, Altundag MB
J BUON · 2021 · PMID 34761623
PURPOSE: To evaluate the sexual functions of prostate cancer patients receiving radiotherapy (RT) with curative intent. METHODS: Fifty patients with low-risk prostate cancer who responded to the international index of er...
PURPOSE: To evaluate the sexual functions of prostate cancer patients receiving radiotherapy (RT) with curative intent. METHODS: Fifty patients with low-risk prostate cancer who responded to the international index of erectile function (IIEF) questionnaire before and after RT were included in the study Results: Statistically significant decline was observed in sexual functions by the end of RT. While the average sexual desire scores of the patients before RT was 6.24, it decreased to 3.62 (p=0.001) after RT. The average of sexual satisfaction scores dropped from 8.94 to 4.6 (p=0.001), the average of erection function scores dropped from 20.14 to 11.76 (p=0.001), orgasmic function scores dropped from 9.6 to 3.9 (p=0.001) and the average of overall satisfaction scores dropped from 7.48 to 4.36 (p=0.001). CONCLUSION: Sexual functions evaluated by the IIEF questionnaire decrease by the end of RT.
Development and validation of a nomogram for specific survival in osteosarcoma patients less than 60 years old: a population-based study.
Zhao J, Jiao J, Su Y … +1 more , Mu L
J BUON · 2021 · PMID 34761622
PURPOSE: The present study aimed to develop a nomogram to predict the overall survival of patients with osteosarcoma, especially those less than 60 years old. METHODS: 903 osteosarcoma patients less than 60 years old wer...
PURPOSE: The present study aimed to develop a nomogram to predict the overall survival of patients with osteosarcoma, especially those less than 60 years old. METHODS: 903 osteosarcoma patients less than 60 years old were collected from the Surveillance, Epidemiology, and End Results (SEER) database.Univariate and multivariate analyses identified the independent prognostic factors of osteosarcoma. Nomogram was used to predict 3- and 5-year overall survival (OS) of osteosarcoma.The accuracy of the model was determined using the concordance index (C‑index), calibration curves, the area under the receiver operating characteristic curves (ROC),as well as decision curve analysis (DCA). RESULTS: Osteosarcoma patients less than 60 years old were randomly assigned into a training cohort (n=635) or validation cohort (n=268). Age, tumor site, tumor grade, tumor size, and tumor stage were identified as independent prognostic factors via univariate and multivariate Cox analyses (all p<0.05) and then included in the prognostic nomogram. The concordance indices(C-index) for OS prediction in the training cohort was 0.788 (95% CI 0.751-0.852) and in the external validation cohort was 0.779 (95% CI 0.712-0.846). Calibration plots and the area under the ROC revealed excellent consistency between actual survival and nomogram prediction. Finally, DCA demonstrated that the prognostic nomogram was clinically meaningful. CONCLUSION: A nomogram could accurately predict the OS of osteosarcoma patients less than 60 years old and contribute to making better clinical treatment decisions for the treating doctors.
FAT10 stimulates the development of osteosarcoma by regulating the JAK/STAT signaling pathway.
Shi F, Li L, Cheng Y
J BUON · 2021 · PMID 34761621
PURPOSE: To investigate the potential function of FAT10 in the development of osteosarcoma (OS) and its mechanism. METHODS: Relative level of FAT10 in OS specimens and cell lines was detected by qRT-PCR. The correlation...
PURPOSE: To investigate the potential function of FAT10 in the development of osteosarcoma (OS) and its mechanism. METHODS: Relative level of FAT10 in OS specimens and cell lines was detected by qRT-PCR. The correlation between FAT10 level and clinical features of OS patients was assessed by χ2 test. After intervention of FAT10 in MG-63 and U2OS cells, changes of FAT10 level, cell viability, clonality and proliferative capacity were respectively detected by qRT-PCR, CCK-8, colony formation and EdU assay. Moreover, dynamic change of FAT10 in OS cells induced with pro-inflammatory factors was examined by qRT-PCR. Protein levels of FAT10, p-STAT1, p-STAT3 and p-STAT5 in OS cells induced with TNF-α were determined by Western blot. The JAK2 inhibitor AZ960 was used to further confirm the role of the JAK signaling in FAT10-regulated development of OS. RESULTS: FAT10 was upregulated in OS specimens and cell lines, which was correlated to tumor size, WHO grade and distant metastasis of OS patients. Knockdown of FAT10 inhibited viability, clonality and proliferative capacity of MG-63 and U2OS cells. FAT10 was time-dependently upregulated in OS cells stimulated with IFN-γ and TNF-α, which was dose-dependently downregulated by the treatment of AZ960. Protein levels of FAT10, p-STAT1, p-STAT3 and p-STAT5 in OS cells induced with AZ960 were remarkably downregulated. CONCLUSION: FAT10 is upregulated in OS samples, which stimulates the development of OS by activating the JAK/STAT signaling pathway.
DDX46 accelerates the proliferation of glioblastoma by activating the MAPK-p38 signaling.
Ma J, Gao Z, Liu X
J BUON · 2021 · PMID 34761620
PURPOSE: To analyze the influence of DDX46 on the proliferative and migratory potentials of glioblastoma (GBM). METHODS: Differential levels of DDX46 in GBM cases and controls were examined by quantitative real-time poly...
PURPOSE: To analyze the influence of DDX46 on the proliferative and migratory potentials of glioblastoma (GBM). METHODS: Differential levels of DDX46 in GBM cases and controls were examined by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. By intervening DDX46 in U87 and U251 cells, proliferative and migratory changes were determined by colony formation assay, 5-Ethynyl-2'- deoxyuridine (EdU) assay and Transwell assay, respectively. Protein levels of p-p38, p38, cyclin D1 and MMP7 in GBM cells intervened by DDX46 or the inhibitor of p38 MAPK were detected. RESULTS: DDX46 was upregulated in GBM cases. Knockdown of DDX46 attenuated the proliferative capacity of GBM cells, and its overexpression enhanced the proliferative rate. The migratory capacity of GBM was not affected by DDX46. Overexpression of DDX46 upregulated p-p38 and cyclin D1 in GBM cells. The regulatory effect of DDX46 on GBM proliferation could be partially reversed by the treatment of doramapimod. CONCLUSIONS: DDX46 is upregulated in GBM, which strengthens the proliferative capacity of GBM by activating the MAPK-p38 signaling.
Serpin peptidase inhibitor, clade E nexin group 1 promotes cellular proliferative capacities and malignant behaviors in glioblastoma through upregulating hairy and enhancer of split-1.
Ma T, Qian K, Xu T … +4 more , Wang X, Qian T, Shi J, Li L
J BUON · 2021 · PMID 34761619
PURPOSE: Glioblastoma (GBM) remains one of the most fatal malignancy with limited available treatment. Serpin peptidase inhibitor, clade E nexin group 1 (SERPINE1) was found up-regulated in multiple cancers and play cruc...
PURPOSE: Glioblastoma (GBM) remains one of the most fatal malignancy with limited available treatment. Serpin peptidase inhibitor, clade E nexin group 1 (SERPINE1) was found up-regulated in multiple cancers and play crucial roles in facilitating tumor progression and metastasis respectively. However, the role of SERPINE1 in glioblastoma was poorly understood. METHODS: We tested the hypothesis that SERPINE1 mediated malignant behaviors in GBM via regulating hairy and enhancer of split-1 (HES1). RESULTS: First, SERPINE1 is confirmed to be up-regulated in GBM, while further functional analysis demonstrated that SERPINE1 promoted cell proliferation, migration and invasion in GBM by performing the CCK-8 assay, colony formation assay, wound healing assay and transwell assay. Finally, it was proved that SERPINE1 achieved its pro-tumor functions in GBM via regulating the expression of HES1. CONCLUSIONS: Collectively, our results highlight the critical contribution of SERPINE1 in a series of malignant characteristics of GBM via regulating the expression of HES1, which shed new light on a new direction to develop a more effective therapeutic management of malignant tumors like GBM.
Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
Halit Aktepe O, Sinem Ardic F, Yuce D … +11 more , Can Guven D, Guner G, Cagri Yildirim H, Kilickap S, Turker A, Kertmen N, Akin S, Aksoy S, Dizdar O, Yalcin S, Erman M
J BUON · 2021 · PMID 34761618
PURPOSE: The objective of the present study was to compare the efficacy of axitinib and nivolumab in metastatic renal cell carcinoma (mRCC) previously treated with targeted therapy. METHODS: A total of 79 patients were e...
PURPOSE: The objective of the present study was to compare the efficacy of axitinib and nivolumab in metastatic renal cell carcinoma (mRCC) previously treated with targeted therapy. METHODS: A total of 79 patients were enrolled (39 patients in axitinib group, 40 patients in nivolumab group). Survival outcomes of patients, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method and compared with the log-rank test. The associations between potential prognostic variables and OS were evaluated in univariate and multivariate Cox regression analyses. RESULTS: The median PFS and OS of all cohort were 8.1 and 36.6 months, respectively. Higher PFS and OS were evaluated in axitinib group than nivolumab group (PFS: 9.4 months vs 6.3 months, p=0.386; OS: 38.2 months vs 36.6 months, p=0.671, respectively). Patients treated with axitinib had numerically higher objective response rate (ORR) and disease control rate (DCR) than those treated with nivolumab (ORR: 43.6% vs 27.6%, p=0.157, DCR: 74.4% vs 62.5%, p=0.157, respectively). Multivariate analysis revealed that the independent predictors of OS were higher tumor grade (hazard ratio [HR]: 6.178, p=0.004), worse response to axitinib and nivolumab (HR:4.902, p=0.011), the presence of lung metastasis (HR:15.637, p=0.002) and the presence of liver metastasis (HR:12.010, p=0.001). CONCLUSION: Comparable survival outcomes were detected in the axitinib and nivolumab groups. However, head to head comparisons are needed to highlight the relative efficacy of these therapies in mRCC.
Expression of miR-410 in peripheral blood of patients with clear cell renal cell carcinoma and its effect on proliferation and invasion of Caki-2 cells.
Liu Z, Zhang J, Hu X … +3 more , Ge Q, Xiao J, Novalinda Ginting C
J BUON · 2021 · PMID 34761617
PURPOSE: To explore the significance of miR-410 expression in clear cell renal cell carcinoma (CCRCC) and its biological function in CCRCC. METHODS: A total of 113 patients with CCRCC admitted to our hospital and 113 hea...
PURPOSE: To explore the significance of miR-410 expression in clear cell renal cell carcinoma (CCRCC) and its biological function in CCRCC. METHODS: A total of 113 patients with CCRCC admitted to our hospital and 113 healthy individuals over the same period were enrolled. MiR-410 in the tissues and serum of patients with CCRCC was quantified, and the diagnostic value of miR-410 in CCRCC and the relationship between miR-410 and prognosis of patients with CCRCC were analyzed. In addition, miR-410 mimic and miR-410 inhibitor were adopted to regulate miR-410 in CCRCC cells (Caki-2), and then the changes in the proliferation, migration, invasion, and cell cycle of Caki-2 cells were determined. Moreover, tumorigenicity in nude mice was carried out to determine the effect of miR-410 on the tumor growth of CCRCC. RESULTS: MiR-410 was expressed at a high level in CCRCC patients, and had a high diagnostic accuracy [area under the curve (AUC) = 0.916]. In addition, miR-410 was an independent risk factor for the survival prognosis of patients with CCRCC, and its high expression indicated poor prognosis of the patients. Inhibiting miR-410 suppressed cell proliferation, cycle progression, migration, invasion and tumor growth in vivo and promoted cell apoptosis. CONCLUSION: MiR-410 is a possible biological indicator for the diagnosis and prognosis of CCRCC, and is also an independent risk factor for the survival prognosis of CCRCC patients. In addition, miR-410 plays a role as an oncogene in CCRCC and promotes the malignant progression of CCRCC.
Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
Wang X, Kong W, Wang Y … +4 more , Wang Y, Chen Y, Shi Z, Liu Y
J BUON · 2021 · PMID 34761616
PURPOSE: This study aimed to investigate the computed tomography (CT) and magnetic resonance imaging (MRI) features of different histological types of renal cell carcinoma (RCC) (clear cell RCC (ccRCC), papillary RCC (pR...
PURPOSE: This study aimed to investigate the computed tomography (CT) and magnetic resonance imaging (MRI) features of different histological types of renal cell carcinoma (RCC) (clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC). METHODS: The clinical data of 67 patients (including 38 patients with ccRCC, 20 patients with pRCC and 9 patients with chRCC) with RCC confirmed pathologically in the Affiliated Hospital of Jining Medical University were retrospectively analyzed. All patients underwent CT, MRI plain scan and three-phase enhanced scan, and their CT and MRI imaging features were analyzed. RESULTS: Most of the enhancement was non-uniform. Most of the lesions presented as "fast-in, fast-out", with obvious enhancement in the early stage and enhancement decline in the later stage. Non-uniform and slightly higher signals were mostly present in DWI. The CT scan of pRCC patients showed equal density and homogeneous enhancement. Some of the larger lesions showed cystic necrosis and hemorrhage. MRI showed a lower signal on T1WI and a slightly higher signal on T2WI. The CT of patients with chRCC showed equal density and more uniform enhancement. DWI showed high signal, and central radial scar showed low signal. There was a significant difference in the percentage of cystic necrosis in ccRCC, pRCC and chRCC among groups (p<0.05). The incidence of cystic necrosis in ccRCC and pRCC was significantly higher than that in chRCC (p<0.05). The CT values in ccRCC patients were significantly higher than those in pRCC and chRCC patients in the parenchymal phase, corticomedullary phase and excretory phase (p<0.05). The CT value of chRCC patients in the parenchymal phase was significantly higher than that of pRCC (p<0.05). CONCLUSION: The CT and MRI of ccRCC, pRCC and chRCC have their own imaging characteristics, which has important reference value for the preoperative differential diagnosis of RCC.
Integrated analysis of hub gene expression in multiple myeloma.
Huang Y, Huang J, Zhang P … +4 more , Luo J, Cheng P, Miao L, Lai Y
J BUON · 2021 · PMID 34761615
PURPOSE: To explore the expression and clinical significance of factors associated with multiple myeloma (MM) and identify new diagnostic markers. METHODS: Two gene expression array data sets (GSE6477 and GSE5900) were d...
PURPOSE: To explore the expression and clinical significance of factors associated with multiple myeloma (MM) and identify new diagnostic markers. METHODS: Two gene expression array data sets (GSE6477 and GSE5900) were downloaded and differentially expressed genes (DEGs) in bone marrow from patients with MM and healthy donors analyzed. Kyoto Encyclopedia of Genes and Genomes pathway enrichment and Gene Ontology annotation of DEGs was conducted and a protein-protein interaction network generated. Plasma and bone marrow samples from patients with MM were analyzed for cytokine expression by ELISA and correlations between cytokine levels and clinical indicators evaluated. RESULTS: Of 908 DEGs, 416 were up-regulated and 492 down-regulated. Further, 161 proteins pairs and 21 nodes were detected, and eight hub genes (CXCL2, CXCL8, CXCL12, ELANE, LCN2, CX3CL1, CCL13, and CCL27) screened out. Expression levels of CXCL8, CXCL2, CXCL12, LCN2, and CCL13 were low in CD138+ plasma cells, and expression levels of the eight cytokines differed significantly in peripheral blood plasma from patients with MM and healthy controls. ROC curve analysis determined optimal diagnostic thresholds determined for: CCL27 (189 ng/mL), CXCL2 (313 ng/L), CX3CL1 (132 ng/L), CCL13 (235 pg/mL), CXCL8 (884 ng/L), ELANE (50 µg/L), LCN2 (8 µg/L), and CXCL12 (2525 pg/mL). CONCLUSIONS: CX3CL1, CCL13, CXCL8, and CXCL12 levels were positively correlated with those of hemoglobin and β2 microglobulin (β2-MG); CCL27 and CXCL2 with β2-MG; and CCL13 and ELANE with white blood cell count and age, respectively. CCL27, CXCL2, and β2-MG levels were associated with MM incidence.
Regulatory effects of miR-188-5p/XRCC5 on the progression of natural killer/T-cell lymphoma.
Huang Q, Ding S, Zhang H
J BUON · 2021 · PMID 34761614
PURPOSE: Natural killer/T cell lymphoma (NKTCL) is a malignant condition. The molecular pathological mechanism of NKTCL has not been well studied. In this article we tried to study the role of microRNA-188-5p (miR-188-5p...
PURPOSE: Natural killer/T cell lymphoma (NKTCL) is a malignant condition. The molecular pathological mechanism of NKTCL has not been well studied. In this article we tried to study the role of microRNA-188-5p (miR-188-5p) in NKTCL. METHODS: The expression level of miR-188-5p and XRCC5 was examined by quantitative real-time polymerase chain reaction (qRT-PCR). Cell counting kit-8 (CCK-8) assay and colony formation assay were used to assess the ability of cell proliferation. Dual luciferase reporter assay was used to examine the down-stream target of miR-188-5p. Western blotting was utilized to determine XRCC5 expression level. RESULTS: miR-188-5p was down-regulated in NKTCL. High expression of miR-188-5p accelerated cell proliferation. XRCC5 was one of the down-stream targets. Our data indicated that miR-188-5p suppressed NKTCL progression via regulating XRCC5 expression. CONCLUSIONS: This research elucidated that miR-188-5p suppressed tumor progression in NKTCL by regulating XRCC5. Our data may provide more evidence in looking for novel therapeutic targets.
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S, Sinan Dal M, Kizil Cakar M … +3 more , Merdin A, Ahu Baysal N, Altuntas F
J BUON · 2021 · PMID 34761613
PURPOSE: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2). METHODS: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with vene...
PURPOSE: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2). METHODS: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA). RESULTS: More than half of the patients could go on with venetoclax for only a few months. CONCLUSION: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.
Meta-analysis on the safety and efficacy of early oral feeding after total laryngectomy.
Yi X, Hu C, Peng Y … +4 more , Wen Z, Li X, Ye L, Huang Q
J BUON · 2021 · PMID 34761612
PURPOSE: To evaluate the safety and efficacy of early oral feeding (≤ 3 days) and delayed oral feeding (≥ 7 days) following total laryngectomy. METHODS: Relevant literatures on early and delayed oral feeding following to...
PURPOSE: To evaluate the safety and efficacy of early oral feeding (≤ 3 days) and delayed oral feeding (≥ 7 days) following total laryngectomy. METHODS: Relevant literatures on early and delayed oral feeding following total laryngectomy published before January, 2019 were searched in PubMed, EMBASE, Web of Science, Cochrane Library, CNKI and Wanfang Database. Two reviewers were responsible for selecting literatures, extracting data and cross-check. The incidence of pharyngocutaneous fistula (PCF) was evaluated by calculating OR and 95%CI. Difference in length of stay (LOS) of patients undergoing early oral feeding or delayed oral feeding was compared using standardized mean difference (SMD) and 95%CI. Sensitivity analysis and publication bias examination were conducted. RESULTS: 14 eligible literatures were enrolled, including 1824 patients who underwent total laryngectomy, with 1250 cases of early oral feeding and 574 cases of delayed oral feeding. The incidence of PCF was similar in patients receiving early oral feeding or delayed oral feeding following total laryngectomy (OR=1.12, 95%CI=0.81-1.54). LOS was shorter in cases of early oral feeding than those of delayed oral feeding (SMD=-0.77, 95%CI=-1.18-0.36). Reliable conclusions were obtained without obvious publication bias. CONCLUSIONS: Early oral feeding following total laryngectomy shortens LOS relative to delayed oral feeding. No significant difference in the incidence of PCF is observed between early oral feeding and delayed oral feeding, suggesting that early oral feeding following total laryngectomy is safe and efficacious.
Oral mucositis-related neuropathic pain in head and neck cancer patients receiving radiotherapy or chemo-radiotherapy. A prospective study.
Kouri M, Nicolatou Galitis O, Vadalouca A … +11 more , Kouloulias V, Papadopoulou E, Vardas E, Kyrodimos E, Trichas M, Zygogianni A, Liakouli Z, Galitis E, Siafaka I, Kougioumtzopoulou A, Psyrri A
J BUON · 2021 · PMID 34761611
PURPOSE: Pain due to oral-mucositis (OM) in head and neck cancer (HNC) patients receiving radiotherapy (RT) /chemo-radiotherapy (CRT) can be nociceptive and/or neuropathic. Neuropathic pain (NP) often remains underdiagno...
PURPOSE: Pain due to oral-mucositis (OM) in head and neck cancer (HNC) patients receiving radiotherapy (RT) /chemo-radiotherapy (CRT) can be nociceptive and/or neuropathic. Neuropathic pain (NP) often remains underdiagnosed and untreated. This study's purpose was to identify the presence of OM-induced NP in HNC patients under RT/CRT. METHODS: Pain was assessed using a 0-10 numeric scale (NRS). At an NRS≥5 score, patients completed the Douleur Neuropathique 4 (DN4) questionnaire, where a score ≥4/10 indicates the presence of NP. Mucositis and xerostomia were assessed using the European Organization for Research and Treatment of Cancer and the NRS scales accordingly. Pain medication was documented. RESULTS: Forty patients were recruited; twenty-six (mean age 63.54±13.96 years) completed a DN4 (mean pain NRS 7.46±1.42); five (5/26, 19.23%) had a DN4≥4. The most common NP descriptors were "burning" (34.62%), "electric shocks" (30.77%) and "pins-and-needles" (30.77%). A direct correlation was observed between DN4 and pain, mucositis, and xerostomia (p<0.02). Pain medication was administered to fifteen patients (15/26, 57.69%). Adjuvant medication was administered to one patient with positive DN4 score. CONCLUSIONS: Five (5/26, 19%) of the patients with NRS≥5 developed NP; adjuvant medication to address NP was prescribed to one patient. NP is likely underdiagnosed and undertreated in the HNC population undergoing RT/RC.
Treatment effect of concurrent chemoradiotherapy after surgery and its effect on postoperative swallowing function of patients with locally advanced hypopharyngeal carcinoma.
Wang X, Wang L, Gao L … +2 more , Guo X, Cao H
J BUON · 2021 · PMID 34761610
PURPOSE: To study the treatment effect of concurrent chemoradiotherapy (CCRT) after surgery and its effect on postoperative swallowing function of patients with locally advanced hypopharyngeal carcinoma. METHODS: The cli...
PURPOSE: To study the treatment effect of concurrent chemoradiotherapy (CCRT) after surgery and its effect on postoperative swallowing function of patients with locally advanced hypopharyngeal carcinoma. METHODS: The clinical data of 84 patients with advanced hypopharyngeal carcinoma treated in our hospital were retrospectively analyzed. The patients were randomly divided into experimental group and control group, with 42 cases in each group. After both groups of patients were treated with radical neck dissection, the control group received adjuvant radiotherapy while the experimental group received CCRT. RESULTS: The Burke score in the experimental group after treatment was significantly lower than that in the control group (p<0.001). The objective remission rate in the experimental group was significantly higher than that in the control group (p<0.05). The jitter and shimmer in the experimental group after treatment were significantly lower than those in the control group (p<0.05). The quality of life scores of patients in the two groups after treatment were significantly higher than those before treatment (p<0.001), and the quality of life score in the experimental group was significantly higher than that in the control group (p<0.001). And the incidence of gastrointestinal reactions and neutropenia in the experimental group after treatment was significantly lower than that in the control group (p<0.05). The 3-year cumulative survival rate after surgery in the experimental group was significantly higher than in the control group (p<0.05). CONCLUSIONS: CCRT after surgery can effectively improve the swallowing function of patients with locally advanced hypopharyngeal carcinoma, which is worthy of promotion and application.
Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database.
Chen S, Wang J, Yang L … +2 more , Ji M, Chen S
J BUON · 2021 · PMID 34761609
PURPOSE: To investigate the difference of clinicopathologic characteristics and prognosis between invasive papillary carcinoma (IPC) and invasive ductal carcinoma (IDC) in breast cancer patients, and to further confirm t...
PURPOSE: To investigate the difference of clinicopathologic characteristics and prognosis between invasive papillary carcinoma (IPC) and invasive ductal carcinoma (IDC) in breast cancer patients, and to further confirm the influence of molecular subtype on prognosis of IPC. METHODS: A total of 158,132 eligible patients from 2010 to 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database, of which 348 patients were IPC and 157,784 patients were IDC. We assessed the clinicopathologic characteristics, molecular subtypes and prognostic value of IPC and compared them with those of IDC. RESULTS: IPC was more frequently presented with older age at diagnosis, less proportion of married and white race, lower grade, smaller tumor size, higher rates of negative nodal status, more AJCC stage I disease and HR+/Her2- breast cancer, and was less likely to be treated with mastectomy, chemotherapy, and radiation therapy than IDC (p<0.05). IPC had a better 5-year breast cancer-specific survival (BCSS) and overall survival (OS) rates than IDC. After adjusting confounding and matching the confounding factors, IPC patients were still associated with better BCSS. Regarding patients with specific subtypes, patients with IPC had more HR+/Her2- subtypes. In addition, HR+/Her2--IPC patients had a better BCSS than HR+/Her2--IDC patients, but OS was similar between the two groups. However, BCSS and OS did not differ in the two groups after matching the confounding factors. Subgroup analysis indicated that molecular subtype may be the main confounding factor in IPC prognosis. CONCLUSIONS: IPC showed more favorable behavior than IDC, but prognosis was not as favorable as people once thought. The determination of the appropriate therapeutic regimen for IPC still needs to be made according to risk factors such as histological grade, pathological stage and molecular subtype.
The landscape of angiogenesis subtypes for breast cancer: a comprehensive analysis based on the Cancer Genome Atlas.
Peng XF, Qin FL, Chen WJ … +3 more , Zhang H, Mai ZY, Zeng J
J BUON · 2021 · PMID 34761608
PURPOSE: Breast cancer is a common malignant tumor in women with a poor prognosis. This study aimed to investigate angiogenesis subtypes of breast cancer and unveil the etiology and molecular features of breast cancer. M...
PURPOSE: Breast cancer is a common malignant tumor in women with a poor prognosis. This study aimed to investigate angiogenesis subtypes of breast cancer and unveil the etiology and molecular features of breast cancer. METHODS: Based on the angiogenesis gene set derived from AmiGO2, and breast cancer data in the Cancer Genome Atlas (TCGA), we define a novel cluster of angiogenesis subtypes for patients by consensus clustering. The gene regulation, immune landscape, molecular characteristics, and clinical features as well as enrichment pathways were explored in the angiogenesis subtypes of breast cancer. RESULTS: Two angiogenesis subtypes were established through consensus clustering, among which subtype1 included 275 patients and subtype2 included 813 patients. A total of 643 differential expressed genes and 109 miRNAs were found between the two subtypes. The gene set enrichment analysis showed that the enriched hallmark pathways in subtype2 were related to the cancer tumorigenesis and breast cancer progression, including estrogen response early estrogen response late, epithelial-mesenchymal transition (EMT), especially angiogenesis. The mutant-allele tumor heterogeneity and tumor mutation burden of non-angiogenesis subtype were significantly higher than that in the angiogenesis subtype. The stroma score, immune score and ESTIMATE score were significantly higher in angiogenesis subtype, while the tumor purity in angiogenesis subtype was considerably lower. Finally, most immune checkpoints were expressed higher in the angiogenesis subtype. CONCLUSIONS: The omics analysis has established a novel angiogenesis subtype of breast cancer and identified the characteristics of the immune microenvironment and genomic alteration of breast cancer. Thus, this angiogenesis subtype might provide new evidence for inhibiting the progression and immunotherapy response in breast cancer.
Feasibility of oncoplastic surgery in breast cancer patients with associated in situ carcinoma.
Caziuc A, Andras D, Fagarasan V … +1 more , Dindelegan GC
J BUON · 2021 · PMID 34761607
PURPOSE: Wide surgical margins are needed in order to treat locally the in situ ductal carcinoma of the breast. Breast conserving surgery using oncoplastic techniques in treating in situ ductal carcinoma can be a good op...
PURPOSE: Wide surgical margins are needed in order to treat locally the in situ ductal carcinoma of the breast. Breast conserving surgery using oncoplastic techniques in treating in situ ductal carcinoma can be a good option improving cosmetic and pathological outcome. METHODS: Between January 2019 and July 2019, 76 patients with invasive carcinoma associated with in situ ductal carcinoma were eligible for breast conserving surgery and were admitted to Cluj-Napoca First Surgical Clinic. Patients were divided into two groups, one group with simple lumpectomy and the other group with oncoplastic procedure. RESULTS: 26 patients had oncoplastic surgery while 47 patients underwent simple lumpectomy. Lateral mammoplasty was the most frequent oncoplastic procedure (41.3%). Mean tumor size was 3.19 cm (SD 0.76) in the oncoplastic cohort while in the simple lumpectomy cohort the mean tumor size was 1.20 cm (SD 0.89). Regarding tumor size, better surgical resection margins were obtained using oncoplastic procedure (p=0.051). No difference between groups in terms of perioperative complications was observed (p=0.32). CONCLUSIONS: Breast conserving surgery with oncoplastic techniques are oncologically safe, obtaining better surgical margins in ductal carcinoma in situ.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe